Lv21
108 积分 2026-07-13 加入
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
26天前
已完结
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
26天前
已关闭
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
26天前
已完结
Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer
27天前
已完结
Advancing Postdilution Hemodiafiltration for Global Sustainability: A Japanese Blueprint
3个月前
已完结
A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database
3个月前
已完结
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
3个月前
已关闭
A0549 Pelvic lymph node dissection can be omitted in PSMA-PET/CT–negative prostate cancer: Evidence from a multicenter study
3个月前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
4个月前
已完结